ELAN
Price
$18.43
Change
+$0.96 (+5.50%)
Updated
Sep 5 closing price
Capitalization
9.16B
66 days until earnings call
PAHC
Price
$39.45
Change
+$0.38 (+0.97%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
1.6B
60 days until earnings call
Interact to see
Advertisement

ELAN vs PAHC

Header iconELAN vs PAHC Comparison
Open Charts ELAN vs PAHCBanner chart's image
Elanco Animal Health
Price$18.43
Change+$0.96 (+5.50%)
Volume$6.92M
Capitalization9.16B
Phibro Animal Health
Price$39.45
Change+$0.38 (+0.97%)
Volume$4.9K
Capitalization1.6B
ELAN vs PAHC Comparison Chart in %
Loading...
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELAN vs. PAHC commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a Hold and PAHC is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ELAN: $18.43 vs. PAHC: $39.45)
Brand notoriety: ELAN: Notable vs. PAHC: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ELAN: 91% vs. PAHC: 140%
Market capitalization -- ELAN: $9.16B vs. PAHC: $1.6B
ELAN [@Pharmaceuticals: Generic] is valued at $9.16B. PAHC’s [@Pharmaceuticals: Generic] market capitalization is $1.6B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAN’s FA Score shows that 0 FA rating(s) are green whilePAHC’s FA Score has 1 green FA rating(s).

  • ELAN’s FA Score: 0 green, 5 red.
  • PAHC’s FA Score: 1 green, 4 red.
According to our system of comparison, PAHC is a better buy in the long-term than ELAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAN’s TA Score shows that 5 TA indicator(s) are bullish while PAHC’s TA Score has 5 bullish TA indicator(s).

  • ELAN’s TA Score: 5 bullish, 4 bearish.
  • PAHC’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both ELAN and PAHC are a good buy in the short-term.

Price Growth

ELAN (@Pharmaceuticals: Generic) experienced а +0.44% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was +6.77% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

ELAN is expected to report earnings on Nov 11, 2025.

PAHC is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELAN($9.16B) has a higher market cap than PAHC($1.6B). PAHC has higher P/E ratio than ELAN: PAHC (33.15) vs ELAN (20.94). PAHC YTD gains are higher at: 88.523 vs. ELAN (52.188). PAHC has less debt than ELAN: PAHC (762M) vs ELAN (4.21B).
ELANPAHCELAN / PAHC
Capitalization9.16B1.6B573%
EBITDA1.45BN/A-
Gain YTD52.18888.52359%
P/E Ratio20.9433.1563%
Revenue4.48BN/A-
Total Cash539MN/A-
Total Debt4.21B762M552%
FUNDAMENTALS RATINGS
ELAN vs PAHC: Fundamental Ratings
ELAN
PAHC
OUTLOOK RATING
1..100
5620
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
29
Undervalued
PROFIT vs RISK RATING
1..100
10038
SMR RATING
1..100
7964
PRICE GROWTH RATING
1..100
3936
P/E GROWTH RATING
1..100
91100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (29) in the Pharmaceuticals Major industry is somewhat better than the same rating for ELAN (93) in the Agricultural Commodities Or Milling industry. This means that PAHC’s stock grew somewhat faster than ELAN’s over the last 12 months.

PAHC's Profit vs Risk Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for ELAN (100) in the Agricultural Commodities Or Milling industry. This means that PAHC’s stock grew somewhat faster than ELAN’s over the last 12 months.

PAHC's SMR Rating (64) in the Pharmaceuticals Major industry is in the same range as ELAN (79) in the Agricultural Commodities Or Milling industry. This means that PAHC’s stock grew similarly to ELAN’s over the last 12 months.

PAHC's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as ELAN (39) in the Agricultural Commodities Or Milling industry. This means that PAHC’s stock grew similarly to ELAN’s over the last 12 months.

ELAN's P/E Growth Rating (91) in the Agricultural Commodities Or Milling industry is in the same range as PAHC (100) in the Pharmaceuticals Major industry. This means that ELAN’s stock grew similarly to PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELANPAHC
RSI
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
60%
Bearish Trend 2 days ago
61%
Momentum
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 2 days ago
71%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 2 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 4 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 2 days ago
72%
Aroon
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JMVZX33.710.29
+0.87%
JPMorgan Mid Cap Value R2
IRVAX25.630.19
+0.75%
Voya Russell Large Cap Value Idx Port A
PGEJX27.800.20
+0.72%
George Putnam Balanced R6
ECHSX12.900.05
+0.39%
Eaton Vance Worldwide Health Sci C
MGQAX17.93N/A
N/A
Morgan Stanley Inst Global Stars A

ELAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with VTRS. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAN
1D Price
Change %
ELAN100%
+5.50%
VTRS - ELAN
54%
Loosely correlated
+1.65%
ZTS - ELAN
46%
Loosely correlated
+0.08%
EBS - ELAN
39%
Loosely correlated
-0.66%
PAHC - ELAN
37%
Loosely correlated
+0.97%
TLRY - ELAN
35%
Loosely correlated
+3.48%
More

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with AMRX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
+2.29%
AMRX - PAHC
46%
Loosely correlated
+0.10%
ZTS - PAHC
41%
Loosely correlated
+0.51%
PBH - PAHC
38%
Loosely correlated
-0.24%
ELAN - PAHC
37%
Loosely correlated
+0.69%
VTRS - PAHC
36%
Loosely correlated
-2.09%
More